Early Intervention Linked to Reduced Asthma Severity and Exacerbations

The core clinical question addressed by the study was whether early endoscopic sinus surgery (ESS) is associated with improved long-term asthma outcomes when compared with delayed surgery in patients diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP). The research unequivocally points to a positive correlation: early ESS, defined as surgery occurring six months or less after a CRSwNP diagnosis, was linked to significantly lower rates of moderate and severe persistent asthma. Furthermore, these patients exhibited fewer asthma exacerbations and a reduced reliance on key asthma medications, including long-acting beta-agonists (LABAs), systemic corticosteroids, and advanced biologic therapies.

This "bottom line" finding is particularly noteworthy given the high comorbidity rate between CRSwNP and asthma. These conditions are widely understood to represent a continuum of inflammation affecting both the upper and lower airways. While previous research has established that ESS can alleviate asthma-related symptoms, enhance quality of life, and decrease medication needs in individuals with CRSwNP, the specific impact of surgical timing on the long-term trajectory of asthma morbidity has remained a critical area of inquiry.

Study Design and Methodology: Leveraging a Global Health Data Network

To address this gap, researchers embarked on a retrospective propensity score-matched cohort study, drawing upon data from the TriNetX Research Network. This extensive global federated electronic health record research network encompasses over 107 healthcare organizations and an aggregate of more than 100 million patient records, providing a robust and diverse dataset for analysis.

The study design focused on adult patients diagnosed with CRSwNP who subsequently underwent ESS. These patients were strategically divided into two distinct cohorts: an "early surgery" group, comprising individuals who had ESS within six months of their CRSwNP diagnosis, and a "delayed surgery" group, defined by surgery occurring between one and three years post-diagnosis. To ensure clear differentiation between the groups and minimize potential confounding, patients who underwent surgery between six and twelve months after diagnosis were deliberately excluded from the analysis. The outcomes for both cohorts were meticulously assessed over an extended five-year follow-up period, allowing for the evaluation of long-term effects.

Unpacking the Data: Key Findings and Statistical Significance

The initial identification within the TriNetX network yielded a substantial pool of patients: 27,519 individuals who underwent early ESS and 3,928 who experienced delayed ESS. Crucially, the researchers employed a rigorous 1:1 propensity score matching methodology. This statistical technique aimed to balance the baseline characteristics of the two groups by accounting for demographic factors, pre-existing asthma severity, and the utilization of asthma medications prior to surgery. After this meticulous matching process, 3,683 patients remained in each cohort, ensuring comparable starting points and a similar average follow-up duration of approximately 3.6 years.

The analysis revealed no statistically significant difference in the incidence of new asthma diagnoses between the early and delayed surgery groups (10.8% in the early group versus 10.9% in the delayed group; odds ratio [OR], 0.99; P=0.89). This suggests that the timing of surgery did not influence the initial development of asthma in patients with CRSwNP.

However, the findings dramatically diverged when examining the severity and exacerbation rates of existing asthma. The early ESS cohort demonstrated significantly lower rates of moderate persistent asthma (11.5% compared to 13.5% in the delayed group; OR, 0.84; P=0.012) and severe persistent asthma (6.5% compared to 8.4% in the delayed group; OR, 0.76; P=0.003). Furthermore, patients who received early surgery experienced fewer asthma exacerbations throughout the five-year follow-up period (6.4% in the early group versus 8.1% in the delayed group; OR, 0.78; P=0.005).

The impact of early ESS extended to medication utilization, a critical indicator of asthma control and burden. Significant differences emerged between the cohorts:

  • Long-Acting Beta-Agonists (LABAs): Early ESS was associated with substantially lower use of LABAs (23.7% in the early group versus 29.4% in the delayed group; OR, 0.75; P<0.001). LABAs are a cornerstone therapy for persistent asthma, and reduced reliance suggests better underlying disease control.
  • Corticosteroids: Patients undergoing early surgery also showed a decreased need for corticosteroids (63.7% versus 67.4%; OR, 0.85; P=0.0009). While the study acknowledges it could not differentiate the route of administration (inhaled vs. systemic), a reduction in overall corticosteroid use is a positive indicator.
  • Biologic Therapies: The most advanced and often most expensive asthma treatments, biologics, were also used less frequently in the early ESS group (7.7% versus 10.1%; OR, 0.74; P=0.0004). This points to a potential decrease in the number of patients requiring these intensive interventions.

Beyond clinical outcomes and medication use, the study also observed a statistically significant difference in the final recorded absolute eosinophil counts during follow-up, a marker often associated with eosinophilic inflammation in asthma and CRSwNP. The early surgery cohort exhibited lower eosinophil counts (372 cells/µL versus 618 cells/µL; P=0.04), further supporting the notion of better inflammatory control.

Authors’ Interpretation and Study Limitations

The authors of the study interpret these findings to suggest that earlier intervention with ESS in patients with CRSwNP may lead to a reduction in asthma morbidity and a diminished long-term treatment burden. They posit that by effectively addressing the upper airway inflammation associated with CRSwNP, the inflammatory cascade that often exacerbates or contributes to lower airway disease may be curtailed.

However, the researchers are candid about the inherent limitations of their retrospective study design. These include the potential for residual confounding, where unmeasured factors might influence the observed associations. The absence of pulmonary function testing and validated asthma control scores during the follow-up period prevents a direct assessment of objective lung function and patient-reported control levels. Furthermore, the inability to precisely determine the route of corticosteroid administration and the lack of detailed CRSwNP severity metrics, such as Lund-Mackay scores, represent further constraints. The authors also note that the use of biologics and corticosteroids could reflect the management of either asthma or CRSwNP severity, making it challenging to attribute these solely to asthma outcomes.

Broader Implications for Clinical Practice and Patient Care

The implications of this study are far-reaching for clinicians and patients alike. For years, the relationship between CRSwNP and asthma has been recognized as a complex interplay of inflammatory processes. Endoscopic sinus surgery has been a valuable tool in managing CRSwNP, often with secondary benefits for asthma control. This research, however, elevates the discussion beyond the simple question of whether to perform surgery to the critical consideration of when.

Dr. Ashoke Khanwalkar, MD, in his commentary on the study, highlights the significance of these findings. He emphasizes that while the study’s limitations are acknowledged, it provides robust evidence to support discussions with patients about the role of surgery in managing their inflammatory disease. The findings suggest that a proactive approach, involving earlier surgical intervention for CRSwNP, may not only alleviate sinus symptoms but also proactively mitigate the long-term burden of asthma.

The study’s findings can empower clinicians to have more informed conversations with patients newly diagnosed with CRSwNP, particularly those with a history or predisposition to asthma. The data suggests that delaying ESS for an extended period might lead to a more entrenched and challenging-to-manage asthma, necessitating more aggressive and costly medical interventions.

Future Directions and the Evolving Landscape of Inflammatory Disease Management

While this retrospective study provides a valuable glimpse into the impact of surgical timing, future prospective research is warranted to confirm these findings and further elucidate the mechanisms at play. Randomized controlled trials, though ethically and logistically challenging, would offer the highest level of evidence. Such studies could also incorporate more detailed assessments, including serial pulmonary function testing, validated asthma control questionnaires, and objective measures of sinonasal inflammation.

The continued advancement in understanding the shared inflammatory pathways between CRSwNP and asthma, coupled with the development of novel therapeutic agents, including biologics, underscores the need for integrated care models. This study reinforces the concept that treating the upper airway inflammation effectively can have profound downstream benefits for lower airway disease. As the medical community continues to unravel the intricate connections within the upper and lower airway continuum, the timing of interventions, including ESS, is poised to become an even more critical component of comprehensive patient management.

The citation for the original study is: Oliver JR, et al. Asthma outcomes following early versus delayed sinus surgery in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2026;16:477-483. doi:10.1002/alr.70091.